Transcriptional activation of CBFβ by CDK11
CBFβ
CDK11
Osteosarcoma
Transcription
Journal
Cell communication and signaling : CCS
ISSN: 1478-811X
Titre abrégé: Cell Commun Signal
Pays: England
ID NLM: 101170464
Informations de publication
Date de publication:
14 10 2019
14 10 2019
Historique:
received:
05
07
2019
accepted:
10
09
2019
entrez:
16
10
2019
pubmed:
16
10
2019
medline:
14
7
2020
Statut:
epublish
Résumé
Aberrant expression of cyclin-dependent protein kinases (CDK) is a hallmark of cancer. CDK11 plays a crucial role in cancer cell growth and proliferation. However, the molecular mechanisms of CDK11 and CDK11 transcriptionally regulated genes are largely unknown. In this study, we performed a global transcriptional analysis using gene array technology to investigate the transcriptional role of CDK11 in osteosarcoma. The promoter luciferase assay, chromatin immunoprecipitation assay, and Gel Shift assay were used to identify direct transcriptional targets of CDK11. Clinical relevance and function of core-binding factor subunit beta (CBFβ) were further accessed in osteosarcoma. We identified a transcriptional role of protein-DNA interaction for CDK11 These data establish CBFβ as a mediator of CDK11
Sections du résumé
BACKGROUND
Aberrant expression of cyclin-dependent protein kinases (CDK) is a hallmark of cancer. CDK11 plays a crucial role in cancer cell growth and proliferation. However, the molecular mechanisms of CDK11 and CDK11 transcriptionally regulated genes are largely unknown.
METHODS
In this study, we performed a global transcriptional analysis using gene array technology to investigate the transcriptional role of CDK11 in osteosarcoma. The promoter luciferase assay, chromatin immunoprecipitation assay, and Gel Shift assay were used to identify direct transcriptional targets of CDK11. Clinical relevance and function of core-binding factor subunit beta (CBFβ) were further accessed in osteosarcoma.
RESULTS
We identified a transcriptional role of protein-DNA interaction for CDK11
CONCLUSIONS
These data establish CBFβ as a mediator of CDK11
Identifiants
pubmed: 31610798
doi: 10.1186/s12964-019-0440-5
pii: 10.1186/s12964-019-0440-5
pmc: PMC6792216
doi:
Substances chimiques
CBFB protein, human
0
Core Binding Factor beta Subunit
0
Cyclin-Dependent Kinases
EC 2.7.11.22
Cyclin-dependent kinase 11p110, human
EC 2.7.11.22
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
125Commentaires et corrections
Type : ErratumIn
Références
Blood. 2014 Mar 13;123(11):1729-38
pubmed: 24449215
Cell. 2018 Jun 28;174(1):172-186.e21
pubmed: 29958106
Cancer Lett. 2014 Jan 1;342(1):104-12
pubmed: 24007862
Oncotarget. 2014 Sep 15;5(17):7805-19
pubmed: 25138053
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Nucleic Acids Res. 2006 Jul 1;34(Web Server issue):W243-8
pubmed: 16845003
J Bone Miner Res. 2015 Apr;30(4):715-22
pubmed: 25358268
Cancer Res. 2012 Feb 1;72(3):757-68
pubmed: 22147262
Clin Cancer Res. 2012 Sep 1;18(17):4580-8
pubmed: 22791884
Mol Cancer Ther. 2016 Jul;15(7):1691-701
pubmed: 27207777
J Alzheimers Dis Rep. 2018 Jul 21;2(1):129-137
pubmed: 30480256
Biochem Pharmacol. 2015 Jul 1;96(1):52-64
pubmed: 25931145
J Cell Physiol. 2009 Dec;221(3):560-71
pubmed: 19739101
EMBO Rep. 2006 Apr;7(4):418-24
pubmed: 16462731
J Biol Chem. 2003 Mar 7;278(10):8623-9
pubmed: 12501247
J Biol Chem. 2002 Jan 25;277(4):2589-96
pubmed: 11709559
Nat Commun. 2019 Mar 26;10(1):1373
pubmed: 30914635
Curr Drug Targets. 2016;17(1):2
pubmed: 26687602
Clin Cancer Res. 2009 Dec 15;15(24):7529-7537
pubmed: 20008853
Curr Protoc Bioinformatics. 2009 Sep;Chapter 7:Unit 7.14 7.14.1-35
pubmed: 19728290
Cell. 2014 Nov 20;159(5):1126-1139
pubmed: 25416950
Sci Rep. 2015 May 20;5:10433
pubmed: 25990212
Nature. 1995 Mar 9;374(6518):131-4
pubmed: 7877684
J Cell Physiol. 2013 Dec;228(12):2350-64
pubmed: 23813439
Mol Cell Biol. 2004 Apr;24(8):3188-97
pubmed: 15060143
Sci Signal. 2008 Sep 30;1(39):ra7
pubmed: 18827223
Chem Biol. 1994 Dec;1(4):191-5
pubmed: 9383389
Proc Natl Acad Sci U S A. 2014 Jun 10;111(23):8482-7
pubmed: 24850862
Clin Exp Metastasis. 2005;22(4):319-29
pubmed: 16170668
Mol Cell. 2007 Jul 6;27(1):121-33
pubmed: 17612495
Gynecol Oncol. 2018 May;149(2):350-360
pubmed: 29551565
Curr Med Chem. 2018;25(8):880-888
pubmed: 28814241
J Cell Biol. 2006 Dec 18;175(6):981-91
pubmed: 17158955
Curr Drug Targets. 2019;20(7):716-726
pubmed: 30516105
Genome Res. 1998 Sep;8(9):929-39
pubmed: 9750192
Mol Cancer. 2010 Jun 30;9:171
pubmed: 20591170
Cell Rep. 2012 Nov 29;2(5):1068-76
pubmed: 23122962
Nature. 2008 Sep 25;455(7212):547-51
pubmed: 18794900
J Biol Chem. 2007 Dec 21;282(51):37091-102
pubmed: 17956865
Nat Genet. 2002 Dec;32(4):633-8
pubmed: 12434152
J Cell Physiol. 2010 Nov;225(3):875-87
pubmed: 20607802
Cancer Genet Cytogenet. 2007 Nov;179(1):62-5
pubmed: 17981216
Comput Biol Chem. 2019 Jun;80:152-158
pubmed: 30959271
Brief Bioinform. 2017 Nov 1;18(6):1044-1056
pubmed: 27585944
Nature. 2014 Jul 31;511(7511):616-20
pubmed: 25043025
Expert Rev Hematol. 2015 Feb;8(1):43-56
pubmed: 25348871
Ann Pharmacother. 2019 Feb;53(2):178-185
pubmed: 30099886
Sci Signal. 2015 Sep 08;8(393):rs9
pubmed: 26350902
Biochem Biophys Res Commun. 2005 Jun 17;331(4):1503-9
pubmed: 15883043
Leukemia. 2015 Oct;29(10):1970-80
pubmed: 26165235
Breast Cancer Res. 2015;17:19
pubmed: 25837326
Oncotarget. 2016 Jun 28;7(26):40846-40859
pubmed: 27049727
Methods Mol Biol. 2016;1366:53-65
pubmed: 26585127
Haematologica. 2002 Dec;87(12):1307-23
pubmed: 12495904
Breast Cancer Res. 2011 Oct 27;13(5):R106
pubmed: 22032690
J Orthop Res. 2015 Feb;33(2):199-207
pubmed: 25348612
Sci Rep. 2015 Jun 16;5:11365
pubmed: 26079799
Nucleic Acids Res. 2015 Aug 18;43(14):6860-73
pubmed: 26071952